EMA Refused: Masipro (Masitinib mesilate) — AB Science

View source ↗

Summary

EMA refused Masipro (masitinib mesilate) for mastocytosis; the marketing authorization was not granted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mastocytosis

Drugs mentioned

• Masipro (masitinib mesilate)

Snippet

Status: Refused. Therapeutic area: Mastocytosis. MAH: AB Science. Decision date: 18/12/2017. Orphan medicine